Feature|Videos|January 2, 2025
Final Thoughts
The future of CAR T-cell therapies will continue to improve as they expand to other patients in need.
Advertisement
Episodes in this series
The panelists provide their closing thoughts on CAR T-cell therapies and what they look forward to as these therapies become popular beyond cancer, extending to autoimmune diseases as well. There is hope to remove manufacturing bottleneck so patient demand and access can improve.
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Is FDA Streamlining Regulations in the Biosimilar Space?
2
Eli Lilly’s Jaypirca Achieves Primary Endpoint in Head-to-Head Phase III Study Against Imbruvica Treating CLL/SLL
3
Carvykti Displays Sustained Remissions in Early Use for Relapsed or Refractory Multiple Myeloma
4
When Borders Become Bottlenecks: How Pharma Should Adapt to the New Geopolitical Lens
5
